LAUNCH OF NEXT-GENERATION qPCR INSTRUMENT

Paris, France and Camberley, UK – 13 May 2019 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, today announces its molecular business, Primerdesign, has launched its next-generation genesig® q32 qPCR molecular testing instrument (“q32”), to complement the already revenue generating genesig® q16 instrument (“q16”). 

Compatible with Novacyt’s catalogue of over 550 molecular tests

https://novacyt.com/wp-content/uploads/2019/05/Novacyt-launches-next-generation-qPCR-instrument_final-13-05-19-ENGLISH.pdf